Nantong Senxuan Pharmaceutical Co Ltd gets listed on the Beijing Stock Exchange on Nov 15. [Photo/ntfabu.com]

The much-anticipated listing of Nantong Senxuan Pharmaceutical Co Ltd on the Beijing Stock Exchange took place on Nov 15, when its shares started trading in the Chinese capital – in the wake of the company's transfer from the China's National Equities Exchange and Quotations market, or NEEQ.

Established in April 2003, the company is a subsidiary of Nantong Jinghua Pharmaceutical Co Ltd – a State-owned enterprise located in the Nantong Gangzha Economic Development Zone – in the Chongchuan district of Nantong city, in East China's Jiangsu province.

In July 2020, it issued 60 million shares on the NEEQ – also known as the new third board – to raise 324 million yuan ($50.8 million), becoming one of the first 32 companies listed on the market's selected layer.

Nantong Senxuan Pharmaceutical is mainly engaged in the research and development, production and marketing of active pharmaceutical ingredients or APIs, pharmaceutical intermediates, chemicals intermediates and other products.

It has a number of patented technologies and has to date obtained 19 API registration certificates.

Nantong Senxuan Pharmaceutical is engaged in the R&D, production and sales of APIs, pharmaceutical intermediates, chemicals intermediates and other products. [Photo/ntfabu.com]

The company's flotation on the Beijing Stock Exchange is said to have marked the recognition of Jinghua Pharmaceutical's development vision and capital operations capabilities.

It is understood that Jinghua Pharmaceutical will provide support for Senxuan Pharmaceutical to get proficient in APIs, get specialized in intermediates, get stronger in new materials and get involved in generic and innovative drugs.